Butyrylcholinesterase: Potential importance for the symptoms and progression of cognitive decline in people with dementia

Acta Neurologica Taiwanica

Volumn 12, Issue 3, 2003, Pages 109-113

  Ballard, C G ^a   Perry, E K ^b  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Alzheimer's disease; Butyrylcholinesterase; Cholinesterase inhibitors; Dementia with Lewy bodies

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; RIVASTIGMINE;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; DRUG EFFICACY; HUMAN; LEWY BODY; MOUSE; NONHUMAN; REVIEW; SENILE PLAQUE;

EID: 0041736287     PISSN: 10196099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Gauthier S, Gélinas I, Gauthier L. Functional disability in Alzheimer's disease. Int Psychogeriatr 1997;9:163-5.
2. Ritchie K, Kildea D. Is senile dementia 'age-related' or 'aging-related'? - Evidence from meta-analysis of dementia prevalence in the oldest old. Lancet 1995;346:931-4.
3. Jeste DV, Alexopoulos GS, Bartels SJ, et al. Consensus statement on the upcoming crisis in geriatric mental health. Arch Gen Psychiatry 1999;56:848-53.
4. Davies KL, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403.
5. Perry EK, Perry RH, Blessed G, et al. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977;1:189.
6. Bartus RT, Dean RL 3rd, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-14.
7. Gallagher M, Colombo PJ. Ageing: the cholinergic hypothesis of cognitive decline. Curr Opin Neurobiol 1995;5:161-8.
8. Kasa P, Rakonczay Z, Gulya K. The cholinergic system in Alzheimer's disease. Prog Neurobiol 1997;52:511-35.
9. Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215:1237-9.
10. Katzman R. Alzheimer's disease. New Engl J Med 1986;314:964-73.
11. O'Brien JT, Ballard CG. Drugs for Alzheimer's disease. Br Med J 2001;323:123-4.
12. Quinn DM. Acetylcholinesterase: enzyme structure, reaction dynamics and virtual transition states. Chem Rev 1987;87:955-79.
13. Taylor P, Radic Z. The cholinesterases: from genes to proteins. Ann Rev Pharmacol Toxicol 1994;34:281-320.
14. Atack JR, Perry EK, Bonham JR, et al. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem 1986;47:263-77.
15. Xie W, Stribley JA, Chatonnet A, et al. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J Pharmacol Exp Ther 2000;293:896-902.
16. Li B, Stribley JA, Ticu A, et al. Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J Neurochem 2000;75:1320-31.
17. Giacobini E. Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. In: Giacobini E, ed. Cholinesterases and Cholinesterase Inhibitors. Martin Dunitz Ltd, 2000:181-226.
18. Darvesh S, Grantham DL, Hopkins DA. Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. J Comp Neurol 1998;393:374-90
19. Perry EK, Perry RH, Blessed G, et al. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978;4:273-7.
20. Arendt T, Bruckner MK, Lange M, et al. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - a study of molecular forms. Neurochem Int 1992;21:381-96.
21. Giacobini E, DeSarno P, Clark C, et al. The cholinergic receptor system of the human brain- neurochemical and pharmacological aspects in aging and Alzheimer. In: Nordberg A, Fuxe K, Holmstedt B, eds. Progress in Brain Research. Amsterdam: Elsevier, 1989:335-43.
22. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
23. Ballard CG, McKeith IG, O'Brien K, et al. Regulation of attention and rate of progression of cognitive deficits by butrylcholinesterase in DLB and moderate/severe Alzheimer's disease (abstract). Neurology 2002;58:A42.
24. Perry EK, McKeith IG, Ballard CG. Butyrylcholinesterase and progression of cognitive deficits in dementia with lewy bodies. Neurology In Press.
25. Geula C, Mesulam M. Cholinesterases and the pathology of Alzheimer's disease. Alzheimer Dis Assoc Disord 1995;9:23-8.
26. Mesulam M, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994;36:722-7.
27. Mesulam M, Morán M. Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease. Ann Neurol 1987;22:223-8.
28. Wright C, Geula C, Mesulam M. Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 1993;34:373-84.
29. Guillozet A, Smiley J, Mash D, et al. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997;42:909-18.
30. Barber KL, Mesulam MM, Kraft GA, et al. Butyrylcholinesterase (BuChE) alters the aggregation state of A-beta amyloid. Society for Neuroscience Abstracts 1996;22:1172.
31. Inestrosa NC, Alvarez A, Perez CA, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996;16:881-91.
32. Ikari H, Spangler E, Greig NH, et al. Performance of aged rats in a 14-unit T-maze is improved following chronic treatment with phenserine, a novel long-acting anticholinesterase. NeuroReport 1995;6:481-4.